Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and EACA provide similar blood decreasing effects following TKA or whether one drug provides a superior effect over the other in reducing patients' blood loss.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Miller Orthopedic Specialists
• Collaborators: CHI Health Mercy Hospital; Creighton University Medical Center
• Treatments: Aminocaproic Acid; Tranexamic Acid

Criteria

Inclusion Criteria:

• Persons aged 18 - 90 years who are scheduled to undergo a unilateral total knee replacement surgery

Exclusion Criteria:

• Non-English speaking individuals

• Individuals with a history of deep vein thrombosis or pulmonary embolism within one year

• Individuals with a history of coagulopathy

• Heart stent within one year

• Pre-operative autologous blood donation

• Unwilling or unable to take Coumadin for deep vein thrombosis (DVT) prophylaxis

• Received nonsteroidal anti-inflammatory drug (NSAID) or platelet antiaggregant treatment within five days prior to surgery

• Pre-operative creatinine greater than 1.5mg/dL